Autolus Therapeutics (AUTL) to Release Earnings on Thursday

Autolus Therapeutics (NASDAQ:AUTL) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Autolus Therapeutics to post earnings of ($0.21) per share for the quarter.

Autolus Therapeutics Stock Up 12.6 %

NASDAQ AUTL opened at $2.06 on Thursday. The firm has a market cap of $548.15 million, a P/E ratio of -1.70 and a beta of 2.07. Autolus Therapeutics has a 52-week low of $1.68 and a 52-week high of $6.63. The business’s 50-day moving average price is $2.15 and its 200 day moving average price is $3.09.

Wall Street Analyst Weigh In

AUTL has been the subject of a number of recent analyst reports. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, January 13th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.